Clinical Trial Update: A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation [Phase 2]

View source ↗

Summary

Phase II clinical trial update for Treprilimab in recurrent nasopharyngeal carcinoma after re-irradiation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Treprilimab (null)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN